1. Prins FM, Kerkmeijer LGW, Pronk AA, Vonken EPA, Meijer RP, Bex A, Barendrecht MM. Renal Cell Carcinoma: Alternative Nephron-Sparing Treatment Options for Small Renal Masses, a Systematic Review. J Endourol. 2017;31(10):963–75.
2. Pierorazio PM, Hyams ES, Tsai S, Feng Z, Trock BJ, Mullins JK, Johnson PT, Fishman EK, Allaf ME. Multiphasic enhancement patterns of small renal masses (</=4 cm) on preoperative computed tomography: utility for distinguishing subtypes of renal cell carcinoma, angiomyolipoma, and oncocytoma. Urology. 2013;81(6):1265–71.
3. Kunath F, Schmidt S, Krabbe LM, Miernik A, Dahm P, Cleves A, Walther M, Kroeger N. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane Database Syst Rev. 2017;5:CD012045.
4. Zisman A, Patard JJ, Raz O, Klatte T, Haifler M, Mendlovic S, Sandbank J, Belldegrun AS, Lindner A, Leibovici D, et al. Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings–a multicenter survey. Urology. 2010;76(3):541–6.
5. Chen SH, Wu YP, Li XD, Lin T, Guo QY, Chen YH, Huang JB, Wei Y, Xue XY, Zheng QS, et al. R.E.N.A.L. Nephrometry Score: A Preoperative Risk Factor Predicting the Fuhrman Grade of Clear-Cell Renal Carcinoma. J Cancer. 2017;8(18):3725–32.
6. Chen Z, Shao Y, Fan M, Zhuang Q, Wang K, Cao W, Xu X, He X. Prognostic significance of preoperative C-reactive protein: albumin ratio in patients with clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2015;8(11):14893–900.
7. Klos KL, Sing CF, Boerwinkle E, Hamon SC, Rea TJ, Clark A, Fornage M, Hixson JE. Consistent effects of genes involved in reverse cholesterol transport on plasma lipid and apolipoprotein levels in CARDIA participants. Arteriosclerosis, thrombosis, and vascular biology 2006, 26(8):1828–1836.
8. Gudowska M, Gruszewska E, Cylwik B, Panasiuk A, Filisiak R, Szmitkowski M, Chrostek L. Serum Sialic Acid Concentration and Content in ApoB-Containing Lipoproteins in Liver Diseases. Clinical laboratory. 2016;62(6):1069–74.
9. Borgquist S, Butt T, Almgren P, Shiffman D, Stocks T, Orho-Melander M, Manjer J, Melander O. Apolipoproteins, lipids and risk of cancer. International journal of cancer Journal international du cancer. 2016;138(11):2648–56.
10. Martinez-Salamanca JI, Huang WC, Millan I, Bertini R, Bianco FJ, Carballido JA, Ciancio G, Hernandez C, Herranz F, Haferkamp A, et al. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. European urology. 2011;59(1):120–7.
11. Ito K, Seguchi K, Shimazaki H, Takahashi E, Tasaki S, Kuroda K, Sato A, Asakuma J, Horiguchi A, Asano T. Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma. Oncology letters. 2015;9(1):125–30.
12. Song J, Liu YD, Su J, Yuan D, Sun F, Zhu J. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma. Journal of cellular physiology 2019.
13. Wu F, Zhao ZH, Ding ST, Wu HH, Lu JJ. High mobility group box 1 protein is methylated and transported to cytoplasm in clear cell renal cell carcinoma. Asian Pacific journal of cancer prevention: APJCP. 2013;14(10):5789–95.
14. Drabkin HA, Gemmill RM. Cholesterol and the development of clear-cell renal carcinoma. Curr Opin Pharmacol. 2012;12(6):742–50.
15. Gebhard RL, Clayman RV, Prigge WF, Figenshau R, Staley NA, Reesey C, Bear A. Abnormal cholesterol metabolism in renal clear cell carcinoma. Journal of lipid research. 1987;28(10):1177–84.
16. Tugnoli V, Poerio A, Tosi MR. Phosphatidylcholine and cholesteryl esters identify the infiltrating behaviour of a clear cell renal carcinoma: 1H, 13C and 31P MRS evidence. Oncol Rep. 2004;12(2):353–6.
17. Saito K, Arai E, Maekawa K, Ishikawa M, Fujimoto H, Taguchi R, Matsumoto K, Kanai Y, Saito Y. Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma. Scientific reports. 2016;6:28932.
18. Mancini M, Postiglione A, di Marino L. Feedback regulation of metabolism by dietary constituents: lipids. Nutrition metabolism. 1977;21(1–3):13–25.
19. Bi Y, Shi X, Zhu J, Guan X, Garbacz WG, Huang Y, Gao L, Yan J, Xu M, Ren S, et al: Regulation of Cholesterol Sulfotransferase SULT2B1b by Hepatocyte Nuclear Factor 4alpha Constitutes a Negative Feedback Control of Hepatic Gluconeogenesis. Molecular and cellular biology 2018, 38(7).
20. Konrad E, Guralp O, Shaalan W, Elzarkaa AA, Moftah R, Alemam D, Malik E, Soliman AA. Correlation of elevated levels of lipoprotein(a), high-density lipoprotein and low-density lipoprotein with severity of preeclampsia: a prospective longitudinal study. Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology 2019:1–6.
21. Goulinet S, Chapman MJ. Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol. 1997;17(4):786–96.
22. Yu Q, Zhang Y, Xu CB. Apolipoprotein B, the villain in the drama? Eur J Pharmacol. 2015;748:166–9.
23. Satoh N, Wada H, Ono K, Yamakage H, Yamada K, Nakano T, Hattori M, Shimatsu A, Kuzuya H, Hasegawa K. Small dense LDL-cholesterol relative to LDL-cholesterol is a strong independent determinant of hypoadiponectinemia in metabolic syndrome. Circulation journal: official journal of the Japanese Circulation Society. 2008;72(6):932–9.
24. Royo-Bordonada MA, Garces C, Gorgojo L, Martin-Moreno JM, Lasuncion MA, Rodriguez-Artalejo F, Fernandez O, de Oya M, Four Provinces S. Saturated fat in the diet of Spanish children: relationship with anthropometric, alimentary, nutritional and lipid profiles. Public Health Nutr. 2006;9(4):429–35.
25. Yu SY, Ryu HK, Park HJ, Choi YJ, Huh KB, Kim WY. Adiponectin gene SNP 276G --> T, nutrient intakes, and cardiovascular disease risk in Korean type 2 DM patients. Nutrition research practice. 2007;1(4):363–70.
26. Liu X, Zheng W, Wang W, Shen H, Liu L, Lou W, Wang X, Yang P. A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. British journal of cancer. 2017;117(12):1846–54.
27. Gao F, Chattopadhyay A, Navab M, Grijalva V, Su F, Fogelman AM, Reddy ST, Farias-Eisner R. Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1alpha in human ovarian cancer cell lines and a mouse ovarian cancer model. J Pharmacol Exp Ther. 2012;342(2):255–62.
28. Wan G, Zhaorigetu S, Liu Z, Kaini R, Jiang Z, Hu CA. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem. 2008;283(31):21540–9.